Display Settings:

Format

Send to:

Choose Destination
    Blood. 2009 Jul 2;114(1):144-7. Epub 2009 May 6.

    Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

    Source

    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

    Abstract

    Disease alleles that activate signal transduction are common in myeloid malignancies; however, there are additional unidentified mutations that contribute to myeloid transformation. Based on the recent identification of TET2 mutations, we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Sequencing of TET2 in 408 paired tumor/normal samples distinguished between 68 somatic mutations and 6 novel single nucleotide polymorphisms and identified TET2 mutations in MPN (27 of 354, 7.6%), CMML (29 of 69, 42%), AML (11 of 91, 12%), and M7 AML (1 of 28, 3.6%) samples. We did not identify somatic TET1 or TET3 mutations or TET2 promoter hypermethylation in MPNs. TET2 mutations did not cluster in genetically defined MPN, CMML, or AML subsets but were associated with decreased overall survival in AML (P = .029). These data indicate that TET2 mutations are observed in different myeloid malignancies and may be important in AML prognosis.

    PMID:
    19420352
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2710942
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk